Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

RUI XING China

Founded in June 2019, with a focus on high-performance medical devices, the Innovation Center of High-Performance Medical Device is devoted to boosting collaboration as well as in-depth integration and innovation of the "Clinical Practice - Scientific Research - Industry - Market"
ecosystem to build high-quality industrial clusters of medical devices by aggregating and utilizing the innovation resources of the Guangdong-Hong Kong-Macao Greater Bay Area and also international resources based on solid clinical practice and industrial basis of Guangdong Province.
Website:
http://www.ihm-gba.com/
Partnering Objectives
Headquartner in China
Yes
IHM GBA
BD director 

Henry Xiong China

Sinovant Sciences (http://www.sinovant.com) is an innovative biopharmaceutical company based in Shanghai, Beijing and Hong Kong. Sinovant was founded by Chinese scientists and physicians, including Chinese “Returnees”. Sinovant is uniquely positioned to bring cutting-edge global medical innovation to China, and transformative Chinese medical innovation to the world.  

   

Sinovant has a diverse pipeline of 11 investigational products in development, among which 5 drug candidates are in phase III or beyond. Our products span over 6 therapeutic areas including oncology, infectious disease, urology / nephrology, gastrointestinal diseases, dermatology and rare diseases. 

Website:
http://www.sinovant.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Sinovant
Senior BD Director 

Dr. June Xu China

医疗基金
Website:
Redhillcapital.cn
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Investment opportunities
Headquartner in China
Yes
丹麓资本
Senior Associate 

Mr. Adam Xu China

Founded in 2007, T&W Group specializes in developing, manufacturing and supplying fine chemicals in Pharmaceuticals, Agrochemicals, Photosensitive Materials, UV Curing Coatings, Brightener, OLED & Electronic Chemicals and other specialty chemicals. We also have R&D center focusing on CDMO projects for our customer.
Website:
www.trustwe.com
Company Size (Fulltime employees)
11-50
Year of foundation
2007
Partnering Objectives
Please specify your partnering goal
Pharmaceuticals, Agrochemicals, Photosensitive Materials, UV Curing Coatings, Brightener, OLED & Electronic Chemicals and other specialty chemicals.
Headquartner in China
Yes
Shanghai T&W Pharmaceutical Co., Ltd.
BD Director 
Functionality
Business Development

wenlian xu China

New drug development
Website:
GHtherapeutics.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
GH Therapeutics
CEO 

Zheng Xu China

Leading Investment and security company in China
Website:
https://www.gtja.com/content/m/index.html
Partnering Objectives
Headquartner in China
Yes
Guotaijunan security
Director 

Mr. Kenneth Xu China

Genova Inc., a bio-pharma company dedicated in the innovation of better protein-drugs for viral diseases, cancer and auto-immune diseases. Novaferon ，the first novel protein drug of Genova, shows antiviral efficacy on viral clearance in a proof of concept randomized clinical trial and approved by Healthcare Canada and PMDA of Japan entering into phase 3 multinational centers clinical trial in last December. We are right looking for strategic parthership with big pharma. Contact: ctxu@genova.cn

Website:
www.genova.cn
Company Size (Fulltime employees)
201-500
Year of foundation
2006
Partnering Objectives
Please specify your partnering goal
To work with a reputable pharmaceutical, or medical institute, or government agency, on scientific and business development of Novaferon as an antiviral drug for COVID-19. Cooperating specifically on organizing and managing international clinical trials, laboratory and animal studies for COVID-19. Licensing rights for COVID-19 applications of Novaferon in defined territories, further equity cooperation might be accordingly considered
Headquartner in China
Yes
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Genova Inc
Vice President & Corporate Secretary 
Functionality
Business Development

Mrs. Shirley Xu China

Yonghua Capital is an institutional investor, with headquarter in Shanghai and portfolio overseas. We have invested in over 40 companies in healthcare field over past 5 years.
Website:
http://www.yonghuacapital.com.cn/
Partnering Objectives
Headquartner in China
Yes
Yonghua Capital
Executive Director 
Functionality
Investment

Siyuan Xu China

VISEN Pharmaceuticals, headquartered in Shanghai, China, is committed to the treatment of endocrine-related disease, introducing the world’s leading treatment methods and drugs into the China market, benefiting Chinese patients while unleashing product potential.

VISEN Pharmaceuticals (VISEN) was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma’s endocrinology rare disease therapies in Greater China. The pipeline of VISEN covers pediatric endocrinology, adult endocrinology, and rare disease. VISEN management team has extensive experience in the development and commercialization of endocrine disease products in Greater China. VISEN has a deep understanding of unmet medical needs in Chinese patients and is actively expanding its pipeline through in-licensing and partnership.
Website:
www.visenpharma.com
Partnering Objectives
Headquartner in China
Yes
VISEN Pharmaceutical
Senior BD Manager 

Mr. Evan Xu China

Genetron Holdings Limited (“Genetron Health” or the “Company”) (Nasdaq: GTH) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The Company has developed a comprehensive oncology portfolio that covers the entire spectrum of cancer management, addressing needs and challenges from early screening, diagnosis and treatment recommendations, as well as continuous disease monitoring and care. Genetron Health also partners with global biopharmaceutical companies and offers customized services and products.
Website:
ir.genetronhealth.com
Company Size (Fulltime employees)
501-1000
Year of foundation
2015
Partnering Objectives
Please specify your partnering goal
N/A
Headquartner in China
Yes
Genetron Health
Chief Financial Officer 
Functionality
Management